Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TNGX
Upturn stock ratingUpturn stock rating

Tango Therapeutics Inc (TNGX)

Upturn stock ratingUpturn stock rating
$6.92
Last Close (24-hour delay)
Profit since last BUY266.14%
upturn advisory
Strong Buy
BUY since 59 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TNGX (3-star) is a STRONG-BUY. BUY since 59 days. Profits (266.14%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $10.86

1 Year Target Price $10.86

Analysts Price Target For last 52 week
$10.86 Target price
52w Low $1.03
Current$6.92
52w High $12.02

Analysis of Past Performance

Type Stock
Historic Profit 377.16%
Avg. Invested days 40
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 769.92M USD
Price to earnings Ratio -
1Y Target Price 10.86
Price to earnings Ratio -
1Y Target Price 10.86
Volume (30-day avg) 8
Beta 1.64
52 Weeks Range 1.03 - 12.02
Updated Date 08/15/2025
52 Weeks Range 1.03 - 12.02
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.32

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate -0.35
Actual -0.35

Profitability

Profit Margin -
Operating Margin (TTM) -1287.87%

Management Effectiveness

Return on Assets (TTM) -31.74%
Return on Equity (TTM) -76.09%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 624143909
Price to Sales(TTM) 31.69
Enterprise Value 624143909
Price to Sales(TTM) 31.69
Enterprise Value to Revenue 25.69
Enterprise Value to EBITDA -0.91
Shares Outstanding 111260000
Shares Floating 48379293
Shares Outstanding 111260000
Shares Floating 48379293
Percent Insiders 12.26
Percent Institutions 96.54

ai summary icon Upturn AI SWOT

Tango Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel cancer therapeutics. Founded in 2017, the company leverages its functional genomics platform to identify and validate novel drug targets in genetically defined cancer patient populations. They went public via IPO in 2021. Their approach is focused on synthetic lethality.

business area logo Core Business Areas

  • Drug Discovery & Development: Tango's primary focus is on identifying and developing novel drug candidates targeting specific cancer vulnerabilities through synthetic lethality. This includes target validation, drug design, preclinical studies, and clinical trials.
  • Functional Genomics Platform: The company utilizes its proprietary functional genomics platform to identify new cancer targets and understand drug resistance mechanisms.
  • Partnerships: Tango collaborates with pharmaceutical companies to accelerate drug development and expand its pipeline. Their most prominent partnership is with Gilead Sciences.

leadership logo Leadership and Structure

Barbara Weber, M.D., is the CEO. The management team consists of experienced professionals in drug discovery, development, and commercialization. The company has a Board of Directors providing strategic oversight.

Top Products and Market Share

overview logo Key Offerings

  • TNG908: TNG908 is Tango's lead clinical program, a MTA-cooperative PRMT5 inhibitor. It is currently in Phase 1/2 clinical trials for MTAP-deleted cancers. There is no direct market share yet, as it is still in clinical development. Competitors in the PRMT5 inhibitor space include companies like Mirati Therapeutics and Artios Pharma.
  • TNGO29: TNGO29 is a preclinical program targeting USP1. It is being developed as a potential treatment for BRCA1/2-mutant cancers and other tumors deficient in DNA damage repair. There is no direct market share yet, as it is still in preclinical development. The competitive landscape includes other companies developing therapies targeting DNA damage repair pathways.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high risk, high reward, and intense competition. Advances in genomics and personalized medicine are driving the development of targeted therapies, including those based on synthetic lethality. The industry is heavily regulated and requires significant capital investment.

Positioning

Tango Therapeutics is positioned as a leader in the field of synthetic lethality. Its functional genomics platform gives it a competitive advantage in identifying and validating novel drug targets. The Gilead partnership validates their technology and provides financial resources.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Tango is positioned to capture a portion of this market by developing therapies for genetically defined cancer patient populations.

Upturn SWOT Analysis

Strengths

  • Proprietary functional genomics platform
  • Strong scientific team
  • Strategic partnership with Gilead Sciences
  • Focus on genetically defined patient populations
  • Novel approach to drug discovery (synthetic lethality)

Weaknesses

  • Early-stage clinical pipeline (high risk)
  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on partnerships for funding
  • No approved products yet

Opportunities

  • Expansion of pipeline through internal discovery and partnerships
  • Advancement of clinical programs to late-stage development
  • Potential for breakthrough therapies in underserved patient populations
  • Increased adoption of personalized medicine approaches

Threats

  • Clinical trial failures
  • Competition from other biotechnology and pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges
  • Economic downturn impacting funding

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • ARTL
  • GILD
  • ARRY

Competitive Landscape

Tango's advantage lies in its functional genomics platform. Its disadvantage is its smaller size and limited resources compared to established pharmaceutical companies. Gilead offers a strong partnership.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily characterized by preclinical and early clinical development activities. They became a public company in 2021.

Future Projections: Future growth depends on the successful development and commercialization of its pipeline. Analyst estimates vary widely based on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing TNG908 through clinical trials, expanding their pipeline of preclinical programs, and exploring new partnerships.

Summary

Tango Therapeutics is an early-stage biotech company with a promising functional genomics platform focused on synthetic lethality. Its Gilead partnership provides significant validation and funding. The success of its lead clinical program, TNG908, and pipeline expansion are key to future growth, but clinical trial risks and competition from larger players remain significant concerns.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Tango Therapeutics' Website
  • Tango Therapeutics' SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies is inherently risky.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tango Therapeutics Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2020-09-03
President, CEO & Director Dr. Barbara L. Weber M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 155
Full time employees 155

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.